STOCK TITAN
  1. Home
  2. News
  3. PCSA

Processa Pharmaceuticals, Inc. Common - PCSA STOCK NEWS

Welcome to our dedicated page for Processa Pharmaceuticals Common news (Ticker: PCSA), a resource for investors and traders seeking the latest updates and insights on Processa Pharmaceuticals Common stock.

Processa Pharmaceuticals, Inc. (symbol: PCSA) is a clinical-stage biopharmaceutical company, founded in October 2017 and headquartered in Hanover, Maryland. The company's mission is to develop products that can significantly improve the survival and quality of life for patients with high unmet medical needs, particularly in the field of oncology.

Processa Pharmaceuticals specializes in the development of Next Generation Chemotherapy (NGC) oncology drug products using a unique 'regulatory science' approach. The company's primary focus is to advance its pipeline of proprietary small molecule oncology drugs. These NGC products are new chemical entities designed to alter the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites, while preserving the original mechanisms of action that kill cancer cells.

The company's current pipeline includes three promising NGC treatments:

  • NGC-Capecitabine (NGC-Cap): This therapy involves Capecitabine administered with PCS6422, aiming to enhance efficacy and reduce side effects.
  • PCS3117 (NGC-Gemcitabine or NGC-Gem): A novel formulation intended to improve the therapeutic profile of Gemcitabine.
  • PCS11T (NGC-Irinotecan or NGC-Iri): Another innovative treatment designed to optimize the benefits of Irinotecan.

Processa Pharmaceuticals is committed to leveraging its expertise in regulatory science to bring these next-generation treatments to market. The company's strategic partnerships and ongoing clinical trials play a crucial role in advancing its mission and providing hope to patients battling cancer. For the latest updates and more information, investors can contact Patrick Lin at plin@processapharma.com.

News

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Rhea-AI Summary
Processa Pharmaceuticals, Inc. announces a reverse stock split to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on the Nasdaq Capital Market. The reverse stock split will reduce the number of outstanding common stock shares from approximately 24.6 million shares to approximately 1.2 million shares, with a split ratio of 1-for-20. The Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol 'PCSA' with the new CUSIP number 74275C304.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.37%
Tags
stock split
-
News

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces CEO George Ng's corporate overview presentation at the Biotech Showcase 2024, focusing on developing next-gen chemotherapeutic drugs for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
conferences
-
News

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) provides interim analysis from its Phase 1b study of Next Generation Capecitabine (NGC-Cap), showing improved safety and efficacy over capecitabine. Patients received lower doses of NGC-Cap resulting in 5-FU exposure up to 10 times greater than capecitabine, with similar side effect profiles. FDA confirms NGC-Cap as a new chemical entity, suggesting higher efficacy and better safety profile. Fireside Chat on December 20, 2023, to discuss the data and corporate strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.36%
Tags
clinical trial
News

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces positive outcomes from a meeting with the FDA regarding the next Phase 2 study for Next Generation Capecitabine ('NGC-Cap') for cancer patients. The FDA provided helpful guidance on the study design and dosage regimen, based on positive interim results from the ongoing Phase 1b study. Processa anticipates beginning enrollment for the Phase 2 study in mid-2024, aiming to provide a better safety/efficacy profile for patients who cannot tolerate existing Capecitabine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.4%
Tags
clinical trial
-
News

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces Dr. David Young, President of Research and Development, will present at the MedInvest Oncology Investor Conference. Processa CEO George Ng will be available for one-on-one meetings with investors at the conference venue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.53%
Tags
conferences
-
News

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is a clinical-stage pharmaceutical company focusing on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for cancer patients. CEO George Ng recently issued a letter to shareholders, emphasizing the company's pivot to focus on oncology drug product development and the potential for safer and more effective chemotherapy treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18%
Tags
none
News

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces the unexpected passing of Director Virgil Thompson at 83. Mr. Thompson served on the Board of Directors since 2017 and was previously on the Board of Directors of Promet Therapeutics, LLC. The company expresses great sadness and gratitude for his leadership and wisdom.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.77%
Tags
management
-
News

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces Dr. David Young, President of Research and Development, will present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas. The conference is on November 16 – 17, 2023, at the Revere Hotel Boston Common. Dr. Young will be available for one-on-one meetings throughout the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.74%
Tags
conferences
-
News

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Rhea-AI Summary
Processa Pharmaceuticals announces the formation of its Oncology Advisory Board to assist in the design of oncology trial protocols, including the anticipated Phase 2 trial for NGC-Cap. The board comprises key opinion leaders from renowned institutions. Processa aims to develop next-generation chemotherapeutic drugs to enhance cancer treatment efficacy and safety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
management
News

Processa Pharmaceuticals to Present at the ThinkEquity Conference

Rhea-AI Summary
Processa Pharmaceuticals to present updated corporate overview at ThinkEquity Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
45.45%
Tags
conferences

FAQ

What is the current stock price of Processa Pharmaceuticals Common (PCSA)?

The current stock price of Processa Pharmaceuticals Common (PCSA) is $0.871 as of December 24, 2024.

What is the market cap of Processa Pharmaceuticals Common (PCSA)?

The market cap of Processa Pharmaceuticals Common (PCSA) is approximately 2.8M.

What is Processa Pharmaceuticals, Inc.?

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation oncology drug products.

When was Processa Pharmaceuticals founded?

Processa Pharmaceuticals was founded in October 2017.

Where is Processa Pharmaceuticals headquartered?

The company is headquartered in Hanover, Maryland.

What is the mission of Processa Pharmaceuticals?

The mission is to develop products that improve the survival and quality of life for patients with high unmet medical needs.

What does NGC stand for?

NGC stands for Next Generation Chemotherapy.

What are the main products in Processa Pharmaceuticals' pipeline?

The main products include NGC-Capecitabine (NGC-Cap), PCS3117 (NGC-Gemcitabine), and PCS11T (NGC-Irinotecan).

What is the unique approach of Processa Pharmaceuticals?

The company uses a 'regulatory science' approach to develop new chemical entities that enhance the properties of FDA-approved cancer drugs.

How can investors get more information about Processa Pharmaceuticals?

Investors can contact Patrick Lin at plin@processapharma.com for more information.

What recent achievements has Processa Pharmaceuticals made?

Recent achievements include advancements in their NGC treatments and ongoing clinical trials.

Does Processa Pharmaceuticals have any partnerships?

Yes, the company engages in strategic partnerships to advance its mission and bring new treatments to market.

Stock PCSA logo
Processa Pharmaceuticals, Inc. Common

Nasdaq:PCSA

PCSA Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

PCSA Stock Data

2.85M
3.41M
8.74%
1.49%
2.24%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HANOVER